Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS reduced its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 16.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 542,874 shares of the company's stock after selling 105,350 shares during the period. Kornitzer Capital Management Inc. KS owned about 2.02% of Castle Biosciences worth $11,715,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. BluePath Capital Management LLC bought a new stake in Castle Biosciences during the 3rd quarter valued at $31,000. Royal Bank of Canada raised its position in Castle Biosciences by 40.5% during the 2nd quarter. Royal Bank of Canada now owns 2,880 shares of the company's stock valued at $39,000 after purchasing an additional 830 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Castle Biosciences by 61.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 1,821 shares of the company's stock valued at $47,000 after acquiring an additional 691 shares during the period. Osaic Holdings Inc. increased its holdings in shares of Castle Biosciences by 37.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,626 shares of the company's stock valued at $50,000 after acquiring an additional 984 shares during the period. Finally, Lazard Asset Management LLC purchased a new position in shares of Castle Biosciences in the 1st quarter valued at $57,000. 92.60% of the stock is owned by institutional investors.

Insider Transactions at Castle Biosciences

In other Castle Biosciences news, Director Daniel Bradbury sold 2,074 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $23.20, for a total transaction of $48,116.80. Following the transaction, the director now owns 33,870 shares in the company, valued at $785,784. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Castle Biosciences news, insider Derek J. Maetzold sold 1,947 shares of the stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $20.35, for a total transaction of $39,621.45. Following the transaction, the insider now owns 65,418 shares in the company, valued at $1,331,256.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Bradbury sold 2,074 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $23.20, for a total value of $48,116.80. Following the transaction, the director now directly owns 33,870 shares of the company's stock, valued at approximately $785,784. The disclosure for this sale can be found here. Insiders have sold 50,062 shares of company stock worth $1,051,065 over the last quarter. 7.70% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages recently weighed in on CSTL. Scotiabank boosted their target price on Castle Biosciences from $33.00 to $37.00 and gave the stock a "sector outperform" rating in a research note on Friday, March 1st. KeyCorp boosted their target price on Castle Biosciences from $25.00 to $28.00 and gave the stock an "overweight" rating in a research note on Friday, March 1st.

Castle Biosciences Stock Up 0.6 %

Shares of CSTL traded up $0.11 during mid-day trading on Friday, reaching $19.31. The company had a trading volume of 129,601 shares, compared to its average volume of 153,253. Castle Biosciences, Inc. has a 52-week low of $9.26 and a 52-week high of $26.70. The stock has a market capitalization of $530.06 million, a P/E ratio of -8.94 and a beta of 0.93. The stock has a 50 day moving average of $21.53 and a two-hundred day moving average of $19.87.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.84) by $0.74. Castle Biosciences had a negative return on equity of 14.92% and a negative net margin of 26.15%. The firm had revenue of $66.12 million for the quarter, compared to the consensus estimate of $51.32 million. On average, sell-side analysts expect that Castle Biosciences, Inc. will post -2.41 earnings per share for the current year.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.